Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 9Sarcoma 1Other solid neoplasm 1Myeloid 1Lymphoid 1

Conditions

Recurrence 1Primary Myelofibrosis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Aortic aneurysm, familial thoracic 4 1

Interventions

Azacitidine 62Cyclophosphamide 49fludarabine phosphate 46fludarabine 46Cytarabine 34Decitabine 32venetoclax 27Tacrolimus 21Specimen Handling 21Whole-Body Irradiation 19Mycophenolic Acid 19Melphalan 19Filgrastim 19Busulfan 19Imatinib Mesylate 18ruxolitinib 17Biopsy 15Dasatinib 14Antilymphocyte Serum 14Granulocyte Colony-Stimulating Factor 13Etoposide 13Clofarabine 13Peripheral Blood Stem Cell Transplantation 12Sirolimus 11Methotrexate 11Ipilimumab 11Injections 11Thiotepa 10Stem Cell Transplantation 10thymoglobulin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × quizartinib × Myeloid × Clear all
NCT00462761 2020-05-11

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

Daiichi Sankyo

Phase 1 Completed
76 enrolled 12 charts
MyeloidOther hematologic neoplasm

Aortic aneurysm, familial thoracic 4, Leukemia, Erythroblastic, Acute, Leukemia, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡